✦ LIBER ✦

Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha

✍ Scribed by Joseph A. Sparano; Janice P. Dutcher; Ronald Kaleya; Geralyn Caliendo; Joseph Fiorito; Sumi Mitsudo; Richard Shechner; Scott J. Boley; Rasim Gucalp; Niculae Ciobanu; Kathleen Grima; Peter H. Wiernik; Lawrence J. Brandt

Book ID: 102672118
Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 770 KB
Volume: 68
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19911001)68:7<1538::aid-cncr2820680714>3.0.co;2-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Infectious complications of subcutaneous

Infectious complications of subcutaneous interleukin-2 and interferon-alpha

✍ Jones, A.L.; O'Brien, M.E.R.; Moore, J.; Cropley, I.; Lorentzos, A.; Jameson, B. 📂 Article 📅 1992 🏛 The Lancet 🌐 English ⚖ 469 KB

Thyroid dysfunction can predict response

Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2α

✍ Reid, I; Sharpe, I; McDevitt, J; Maxwell, W; Emmons, R; Tanner, WA; Monson, JRT 📂 Article 📅 1991 🏛 Nature Publishing Group 🌐 English ⚖ 759 KB

Immunotherapy with interleukin 4/interfe

Immunotherapy with interleukin 4/interferon alpha 2b prolonges survival and causes regression of lung metastases in murine renal carcinoma

✍ D. Brkovic; S. Pomer; R. Weindl; G. Staenler 📂 Article 📅 1995 🏛 Springer-Verlag 🌐 English ⚖ 146 KB

Risk and outcome in metastatic malignant

Risk and outcome in metastatic malignant melanoma patients receiving DTIC, cisplatin, BCNU and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha2a

✍ Hoffmann, R; Müller, I; Neuber, K; Lassmann, S; Buer, J; Probst, M; Oevermann, K 📂 Article 📅 1998 🏛 Nature Publishing Group 🌐 English ⚖ 700 KB

Home therapy with recombinant interleuki

Home therapy with recombinant interleukin-2 and interferon-$alpha;2b in advanced human malignancies

✍ ATZPODIEN, J 📂 Article 📅 1990 🏛 The Lancet 🌐 English ⚖ 540 KB

Salvage immunotherapy with subcutaneous

Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatment

✍ Maffezzini, Massimo; Simonato, Alchiede; Fortis, Claudio 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 466 KB

Immunotherapy with subcutaneous rIL-2 and alpha IFN was administered to stage D3 prostate cancer patients after the failure of secondary treatment with oral estramustine phosphate. Of a total of 15 patients, 2 are in partial response, with estramustine maintained after 44 + and 36 + weeks, respectiv